secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001193125-22-280669
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera reports Q3 net loss $16M; avasopasem NDA on track by year-end
--------------------------------------------------------------------

- Net loss of $16M ($0.60/share) vs $22.6M ($0.86) in Q3 2021; cash $42.8M.
- NDA for avasopasem in radiotherapy-induced severe oral mucositis remains on track for submission by end of 2022.
- One-year ROMAN follow-up showed tumor outcomes and overall survival maintained; 50% reduction in chronic kidney disease (10% vs 20% placebo, p=0.0043).
- Meta-analysis of ROMAN and GT-201 (n=551) showed reductions in SOM incidence, duration, onset, and severity.
- Appointed Eugene P. Kennedy, M.D., as Chief Medical Officer, succeeding Jon T. Holmlund who plans to retire.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522280669/0001193125-22-280669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522280669/d419294d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-280669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer